PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise, Led by Existing Investors

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise, Led

by Existing Investors

LAS VEGAS, August 18, 2025 (BUSINESS WIRE) -

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company") announced today that it has entered into

a securities purchase agreement for a $7.0 million financing with existing investors involving the sale of 7,000 shares of its newly

designated Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible

into an aggregate of 7,000,000 shares of its common stock and unregistered common stock purchase warrants to purchase up to an aggregate

of 7,000,000 shares of its common stock in a private placement. The private placement is expected to close on or about August

19, 2025, subject to the satisfaction of customary closing conditions.

"This financing, priced at a premium to our current market price

and led by our existing investors, reflects strong confidence in PharmaCyte's future," said Josh Silverman, Interim Chief

Executive Officer of PharmaCyte. "It meaningfully strengthens our balance sheet, positions us to enhance shareholder value, and

enables us to continue pursuing strategic alternatives that we believe can maximize long-term returns for our stockholders."

GP Nurmenkari Inc. is acting as the sole placement agent for the private

The shares of preferred stock have a conversion price

of $1.00 per share of common stock and accrue a 7.0% quarterly dividend payable in cash. The warrants have an exercise

price of $1.00 per common share, are exercisable immediately and are exercisable for a term of five years from the date of

issuance. The securities in the private placement were offered and sold in transactions exempt from the registration requirements of

the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the exemption for transactions by an issuer not

involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in

reliance on similar exemptions under applicable state laws. Accordingly, the shares of common stock issuable upon conversion or

exercise of the preferred stock and warrants offered and sold in the private placement may not be offered or sold in the United

States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the

Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC

registering the resale of the shares of common stock issuable upon conversion of the preferred stock and exercise of the warrants

issued in connection with the private placement.

This press release is not an offer to sell, or a solicitation of an

offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale

would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release may contain forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte's

management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking

statements subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from

those discussed in such forward-looking statements. These statements include, without limitation, PharmaCyte's ability to satisfy

closing conditions with respect to the private placement, the completion of the private placement, and the anticipated use of proceeds

with respect to the private placement. Factors that could affect our actual results are included in the periodic reports on

Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only

as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required

by law, whether as a result of new information, future events or otherwise.

Telephone: 917.885.7378

Email: julesa@coreir.com